This KCNQ1-inhibiting effect of gefitinib is implicated in the induction of heart QT prolongation in a guinea pig model, thereby raising a concern of arrythmia when gefitinib is used for NSCLC treatment. This evidence concerns the gene KCNQ1 and cardiac arrhythmia.